FdaApplication
NDA 210607
Identifiers
- fda_app_no: NDA210607
Properties
| Property | Value |
|---|---|
| applicant_name | 60 DEGREES PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2018-08-08 |
Revenue by product
ARAKODA
| Period | Revenue |
|---|---|
| Q2 2026 | $0.2M† |
| Q1 2026 | $0.2M† |
| Q4 2025 | $0.3M† |
| Q3 2025 | $0.4M† |
| Q2 2025 | $0.1M† |
| Q1 2025 | $0.2M† |
| Q4 2024 | $0.2M† |
| Q3 2024 | $0.1M† |
| Q2 2024 | $0.1M† |
| Q1 2024 | $0.1M† |
| Q4 2023 | $0.1M† |
| Q3 2023 | $0.1M† |
| Q3 2022 | $0.2M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ARAKODA | TAFENOQUINE SUCCINATE | EQ 100MG BASE | TABLET;ORAL |
1 product